| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chitosan | 3 | 2024 | 85 | 2.510 |
Why?
|
| Hydrogels | 4 | 2024 | 134 | 2.040 |
Why?
|
| Bandages | 4 | 2024 | 75 | 1.520 |
Why?
|
| Models, Statistical | 8 | 2023 | 1184 | 1.320 |
Why?
|
| Bayes Theorem | 12 | 2023 | 1060 | 1.080 |
Why?
|
| Lymphoma, Mantle-Cell | 8 | 2023 | 750 | 1.070 |
Why?
|
| Research Design | 9 | 2023 | 1569 | 1.070 |
Why?
|
| Muscle, Smooth, Vascular | 4 | 2022 | 329 | 1.030 |
Why?
|
| Wound Healing | 3 | 2024 | 749 | 0.970 |
Why?
|
| Iridoids | 1 | 2024 | 2 | 0.960 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2024 | 67 | 0.940 |
Why?
|
| Cross-Linking Reagents | 1 | 2024 | 167 | 0.900 |
Why?
|
| Staphylococcus aureus | 2 | 2024 | 562 | 0.860 |
Why?
|
| Escherichia coli | 3 | 2024 | 1305 | 0.840 |
Why?
|
| Caveolin 1 | 1 | 2022 | 201 | 0.760 |
Why?
|
| Protein Interaction Mapping | 2 | 2020 | 168 | 0.730 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 2 | 2019 | 264 | 0.720 |
Why?
|
| Drug Approval | 6 | 2019 | 174 | 0.670 |
Why?
|
| Foreign Bodies | 1 | 2021 | 160 | 0.660 |
Why?
|
| Metformin | 1 | 2023 | 393 | 0.640 |
Why?
|
| Clinical Trials as Topic | 7 | 2022 | 3844 | 0.630 |
Why?
|
| Biological Assay | 1 | 2020 | 178 | 0.630 |
Why?
|
| Computer Simulation | 10 | 2021 | 1570 | 0.630 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2019 | 252 | 0.610 |
Why?
|
| RNA, Long Noncoding | 2 | 2021 | 617 | 0.600 |
Why?
|
| Biocompatible Materials | 2 | 2024 | 202 | 0.590 |
Why?
|
| Ubiquitination | 4 | 2016 | 579 | 0.590 |
Why?
|
| Anti-Bacterial Agents | 3 | 2024 | 3187 | 0.550 |
Why?
|
| Ubiquitin-Protein Ligases | 5 | 2022 | 875 | 0.550 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2019 | 550 | 0.530 |
Why?
|
| Membrane Proteins | 6 | 2022 | 2928 | 0.520 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 4 | 2008 | 628 | 0.510 |
Why?
|
| Cadmium Chloride | 1 | 2015 | 5 | 0.510 |
Why?
|
| Drugs, Chinese Herbal | 2 | 2015 | 62 | 0.500 |
Why?
|
| Estrogen Receptor alpha | 1 | 2019 | 692 | 0.490 |
Why?
|
| Environmental Monitoring | 4 | 2019 | 104 | 0.490 |
Why?
|
| Likelihood Functions | 3 | 2023 | 241 | 0.490 |
Why?
|
| Hospital Mortality | 1 | 2020 | 1234 | 0.480 |
Why?
|
| Neuroblastoma | 1 | 2020 | 705 | 0.470 |
Why?
|
| Animals | 36 | 2024 | 61956 | 0.470 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 1024 | 0.460 |
Why?
|
| Peptide Fragments | 1 | 2020 | 1309 | 0.460 |
Why?
|
| Mice | 24 | 2024 | 35600 | 0.450 |
Why?
|
| Hyperuricemia | 2 | 2024 | 47 | 0.430 |
Why?
|
| Hydroxyapatites | 1 | 2012 | 11 | 0.420 |
Why?
|
| Polyvinyl Alcohol | 1 | 2012 | 22 | 0.410 |
Why?
|
| Sample Size | 4 | 2023 | 213 | 0.410 |
Why?
|
| Cells, Cultured | 8 | 2022 | 5694 | 0.410 |
Why?
|
| Air Pollutants | 3 | 2019 | 135 | 0.400 |
Why?
|
| S-Phase Kinase-Associated Proteins | 3 | 2010 | 54 | 0.400 |
Why?
|
| Proteins | 1 | 2020 | 2043 | 0.390 |
Why?
|
| Myocytes, Smooth Muscle | 3 | 2022 | 182 | 0.390 |
Why?
|
| Neovascularization, Physiologic | 1 | 2013 | 346 | 0.380 |
Why?
|
| Antineoplastic Agents | 7 | 2022 | 14617 | 0.380 |
Why?
|
| China | 7 | 2020 | 636 | 0.370 |
Why?
|
| NIH 3T3 Cells | 3 | 2024 | 255 | 0.370 |
Why?
|
| Metals, Heavy | 3 | 2020 | 30 | 0.370 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2021 | 9042 | 0.370 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2010 | 62 | 0.360 |
Why?
|
| Wetlands | 3 | 2020 | 8 | 0.360 |
Why?
|
| DNA-Binding Proteins | 7 | 2020 | 5002 | 0.350 |
Why?
|
| Meta-Analysis as Topic | 3 | 2018 | 274 | 0.340 |
Why?
|
| Tissue Engineering | 1 | 2012 | 253 | 0.340 |
Why?
|
| Groundwater | 2 | 2020 | 13 | 0.340 |
Why?
|
| Porosity | 2 | 2024 | 59 | 0.340 |
Why?
|
| Osteoblasts | 1 | 2012 | 393 | 0.340 |
Why?
|
| Materials Testing | 2 | 2024 | 119 | 0.330 |
Why?
|
| B7-H1 Antigen | 3 | 2021 | 1089 | 0.330 |
Why?
|
| Endothelium, Vascular | 1 | 2013 | 879 | 0.330 |
Why?
|
| Data Interpretation, Statistical | 2 | 2008 | 483 | 0.330 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2019 | 1386 | 0.330 |
Why?
|
| Receptor, Notch1 | 2 | 2008 | 217 | 0.320 |
Why?
|
| Eukaryotic Initiation Factor-3 | 2 | 2019 | 15 | 0.320 |
Why?
|
| Ubiquitin | 4 | 2020 | 331 | 0.320 |
Why?
|
| Drug Stability | 1 | 2008 | 106 | 0.310 |
Why?
|
| Receptors, Notch | 2 | 2010 | 372 | 0.310 |
Why?
|
| Lymphopoiesis | 1 | 2008 | 17 | 0.300 |
Why?
|
| Cooking | 2 | 2019 | 68 | 0.300 |
Why?
|
| Signal Transduction | 10 | 2019 | 12103 | 0.300 |
Why?
|
| Humans | 59 | 2024 | 270740 | 0.300 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2008 | 51 | 0.300 |
Why?
|
| Infectious bronchitis virus | 1 | 2007 | 2 | 0.300 |
Why?
|
| Particulate Matter | 2 | 2019 | 86 | 0.290 |
Why?
|
| Cell Proliferation | 9 | 2023 | 7238 | 0.290 |
Why?
|
| Transcription Factors | 7 | 2020 | 5438 | 0.290 |
Why?
|
| Gallbladder Neoplasms | 2 | 2021 | 244 | 0.290 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 1580 | 0.280 |
Why?
|
| MicroRNAs | 1 | 2020 | 2887 | 0.280 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 2 | 2022 | 153 | 0.280 |
Why?
|
| Viral Matrix Proteins | 1 | 2007 | 181 | 0.270 |
Why?
|
| Neoplasms | 7 | 2022 | 15927 | 0.270 |
Why?
|
| Apoptosis | 5 | 2023 | 7757 | 0.260 |
Why?
|
| Down-Regulation | 4 | 2023 | 2090 | 0.260 |
Why?
|
| Allopurinol | 2 | 2024 | 85 | 0.250 |
Why?
|
| Rats | 7 | 2022 | 6441 | 0.250 |
Why?
|
| Neuropilins | 2 | 2016 | 14 | 0.250 |
Why?
|
| Lung Neoplasms | 4 | 2024 | 12033 | 0.250 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2022 | 3409 | 0.240 |
Why?
|
| Plant Roots | 2 | 2014 | 45 | 0.240 |
Why?
|
| Tryptamines | 1 | 2024 | 7 | 0.230 |
Why?
|
| Maximum Tolerated Dose | 2 | 2018 | 1322 | 0.220 |
Why?
|
| Spectroscopy, Near-Infrared | 2 | 2014 | 172 | 0.220 |
Why?
|
| Diploidy | 1 | 2023 | 116 | 0.220 |
Why?
|
| Tyramine | 1 | 2022 | 5 | 0.220 |
Why?
|
| Adhesives | 1 | 2023 | 13 | 0.220 |
Why?
|
| Free Radicals | 1 | 2023 | 64 | 0.210 |
Why?
|
| Migraine Disorders | 1 | 2024 | 84 | 0.210 |
Why?
|
| Gelatin | 1 | 2022 | 43 | 0.210 |
Why?
|
| Dextrans | 1 | 2023 | 98 | 0.210 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2016 | 669 | 0.210 |
Why?
|
| Interleukin-6 | 3 | 2019 | 1050 | 0.210 |
Why?
|
| United States Food and Drug Administration | 4 | 2019 | 323 | 0.210 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2022 | 66 | 0.200 |
Why?
|
| Medical Futility | 1 | 2022 | 57 | 0.200 |
Why?
|
| Multivariate Analysis | 1 | 2009 | 4328 | 0.200 |
Why?
|
| Phosphorylation | 6 | 2019 | 4942 | 0.200 |
Why?
|
| Gallbladder | 1 | 2021 | 68 | 0.190 |
Why?
|
| Biocatalysis | 1 | 2021 | 64 | 0.190 |
Why?
|
| Endocytosis | 1 | 2022 | 232 | 0.190 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2023 | 5408 | 0.190 |
Why?
|
| Protein Binding | 4 | 2020 | 3485 | 0.190 |
Why?
|
| Circulating Tumor DNA | 1 | 2024 | 274 | 0.190 |
Why?
|
| Volatile Organic Compounds | 2 | 2018 | 13 | 0.190 |
Why?
|
| Binding Sites | 3 | 2020 | 2255 | 0.180 |
Why?
|
| Hyperplasia | 1 | 2022 | 564 | 0.180 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2020 | 56 | 0.180 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2021 | 1642 | 0.180 |
Why?
|
| Biphenyl Compounds | 2 | 2019 | 188 | 0.180 |
Why?
|
| Tomography, Spiral Computed | 1 | 2021 | 128 | 0.180 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2015 | 1367 | 0.180 |
Why?
|
| Antibodies, Neoplasm | 1 | 2021 | 273 | 0.180 |
Why?
|
| Technology | 1 | 2021 | 100 | 0.180 |
Why?
|
| Pyroptosis | 1 | 2020 | 39 | 0.180 |
Why?
|
| Potyvirus | 1 | 2020 | 1 | 0.180 |
Why?
|
| Horseradish Peroxidase | 1 | 2020 | 17 | 0.180 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 1 | 2020 | 25 | 0.180 |
Why?
|
| Indolizines | 1 | 2019 | 46 | 0.170 |
Why?
|
| Telomere | 1 | 2023 | 550 | 0.170 |
Why?
|
| Receptors, Cell Surface | 1 | 2003 | 904 | 0.170 |
Why?
|
| Drug Delivery Systems | 1 | 2024 | 661 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 152 | 0.170 |
Why?
|
| Electrodes | 2 | 1990 | 132 | 0.170 |
Why?
|
| Pyridinium Compounds | 1 | 2019 | 64 | 0.170 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2021 | 809 | 0.170 |
Why?
|
| beta-Galactosidase | 1 | 2020 | 274 | 0.170 |
Why?
|
| Receptors, CCR4 | 1 | 2019 | 35 | 0.170 |
Why?
|
| Triazoles | 1 | 2024 | 627 | 0.170 |
Why?
|
| Cyclic N-Oxides | 1 | 2019 | 97 | 0.170 |
Why?
|
| Bronchi | 1 | 2021 | 325 | 0.170 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2020 | 163 | 0.160 |
Why?
|
| Genetic Variation | 1 | 2007 | 2166 | 0.160 |
Why?
|
| Protein Kinase C-delta | 1 | 2018 | 42 | 0.160 |
Why?
|
| Leptin | 1 | 2020 | 306 | 0.160 |
Why?
|
| Monte Carlo Method | 4 | 2018 | 706 | 0.160 |
Why?
|
| Water Quality | 1 | 2018 | 9 | 0.160 |
Why?
|
| Luciferases | 1 | 2020 | 460 | 0.160 |
Why?
|
| Janus Kinase 1 | 1 | 2019 | 125 | 0.160 |
Why?
|
| Cremation | 1 | 2018 | 1 | 0.160 |
Why?
|
| Carex Plant | 1 | 2018 | 1 | 0.160 |
Why?
|
| Tracheophyta | 1 | 2018 | 2 | 0.160 |
Why?
|
| Mice, Transgenic | 4 | 2019 | 4223 | 0.160 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2023 | 1710 | 0.160 |
Why?
|
| Endopeptidases | 1 | 2020 | 230 | 0.160 |
Why?
|
| Mammary Glands, Human | 1 | 2019 | 182 | 0.160 |
Why?
|
| Hypoglycemic Agents | 1 | 2023 | 599 | 0.160 |
Why?
|
| Soil Pollutants | 1 | 2018 | 13 | 0.150 |
Why?
|
| Mice, Nude | 3 | 2020 | 4329 | 0.150 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 690 | 0.150 |
Why?
|
| Water Pollutants, Chemical | 1 | 2018 | 39 | 0.150 |
Why?
|
| Transportation | 1 | 2018 | 50 | 0.150 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2019 | 183 | 0.150 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2007 | 2617 | 0.150 |
Why?
|
| Up-Regulation | 2 | 2021 | 2422 | 0.150 |
Why?
|
| Vehicle Emissions | 1 | 2018 | 25 | 0.150 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2015 | 2486 | 0.150 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2019 | 217 | 0.150 |
Why?
|
| Morpholines | 1 | 2019 | 296 | 0.150 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2020 | 265 | 0.150 |
Why?
|
| Sezary Syndrome | 1 | 2019 | 171 | 0.150 |
Why?
|
| Heterografts | 1 | 2020 | 738 | 0.150 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2018 | 95 | 0.150 |
Why?
|
| Green Fluorescent Proteins | 1 | 2020 | 693 | 0.150 |
Why?
|
| beta-Lactamases | 1 | 2020 | 223 | 0.150 |
Why?
|
| Tumor Escape | 1 | 2019 | 247 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2019 | 1412 | 0.140 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 444 | 0.140 |
Why?
|
| Toll-Like Receptors | 2 | 2015 | 170 | 0.140 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 1 | 2017 | 80 | 0.140 |
Why?
|
| Pyridones | 1 | 2019 | 360 | 0.140 |
Why?
|
| Neuralgia | 1 | 2020 | 265 | 0.140 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2024 | 5574 | 0.140 |
Why?
|
| Antigens, CD | 3 | 2022 | 1418 | 0.140 |
Why?
|
| Cell Line | 5 | 2008 | 5338 | 0.130 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2020 | 470 | 0.130 |
Why?
|
| Synapses | 1 | 2020 | 546 | 0.130 |
Why?
|
| Neointima | 1 | 2016 | 58 | 0.130 |
Why?
|
| Myocardial Ischemia | 1 | 2019 | 421 | 0.130 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2012 | 600 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 5 | 2021 | 7100 | 0.130 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2016 | 157 | 0.130 |
Why?
|
| Mycosis Fungoides | 1 | 2019 | 341 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2018 | 1137 | 0.130 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2020 | 662 | 0.130 |
Why?
|
| Neoplasms, Experimental | 1 | 2019 | 784 | 0.130 |
Why?
|
| Protein Structure, Tertiary | 3 | 2010 | 1472 | 0.130 |
Why?
|
| Markov Chains | 3 | 2018 | 185 | 0.130 |
Why?
|
| Multiple Myeloma | 2 | 2018 | 2328 | 0.130 |
Why?
|
| Ultrafiltration | 1 | 2015 | 25 | 0.130 |
Why?
|
| Algorithms | 3 | 2018 | 3891 | 0.120 |
Why?
|
| Cytokines | 3 | 2022 | 2825 | 0.120 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2023 | 1838 | 0.120 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2018 | 622 | 0.120 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2015 | 95 | 0.120 |
Why?
|
| Dendrobium | 1 | 2014 | 1 | 0.120 |
Why?
|
| Pueraria | 1 | 2014 | 2 | 0.120 |
Why?
|
| Genome, Human | 1 | 2023 | 1888 | 0.120 |
Why?
|
| Quinazolinones | 1 | 2015 | 52 | 0.120 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2008 | 593 | 0.120 |
Why?
|
| Dipsacaceae | 1 | 2014 | 1 | 0.120 |
Why?
|
| Wine | 1 | 2014 | 20 | 0.120 |
Why?
|
| Probability | 2 | 2022 | 886 | 0.120 |
Why?
|
| Saponins | 1 | 2014 | 48 | 0.120 |
Why?
|
| Castleman Disease | 1 | 2015 | 71 | 0.120 |
Why?
|
| Isoflavones | 1 | 2014 | 74 | 0.120 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2013 | 4 | 0.120 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2013 | 13 | 0.110 |
Why?
|
| Female | 20 | 2024 | 148940 | 0.110 |
Why?
|
| Benzamides | 1 | 2019 | 1879 | 0.110 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2015 | 210 | 0.110 |
Why?
|
| RNA Interference | 2 | 2018 | 1388 | 0.110 |
Why?
|
| Receptors, Progesterone | 1 | 2019 | 1604 | 0.110 |
Why?
|
| Ear, External | 1 | 2013 | 44 | 0.110 |
Why?
|
| Hindlimb | 1 | 2013 | 111 | 0.110 |
Why?
|
| Microfilament Proteins | 1 | 2016 | 494 | 0.110 |
Why?
|
| Cell Line, Tumor | 7 | 2023 | 14849 | 0.110 |
Why?
|
| Lymphoma, Follicular | 2 | 2018 | 636 | 0.110 |
Why?
|
| Insulin | 2 | 2016 | 1483 | 0.110 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2014 | 168 | 0.110 |
Why?
|
| Purines | 1 | 2015 | 271 | 0.110 |
Why?
|
| Colonic Neoplasms | 1 | 2021 | 1435 | 0.110 |
Why?
|
| Retinal Vessels | 1 | 2013 | 82 | 0.110 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2013 | 170 | 0.110 |
Why?
|
| Cullin Proteins | 2 | 2010 | 38 | 0.110 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2019 | 1013 | 0.110 |
Why?
|
| Male | 20 | 2024 | 128315 | 0.110 |
Why?
|
| Uric Acid | 2 | 2024 | 117 | 0.110 |
Why?
|
| RNA, Small Interfering | 3 | 2016 | 2196 | 0.110 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2015 | 529 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2017 | 2069 | 0.100 |
Why?
|
| Lipopolysaccharides | 2 | 2015 | 589 | 0.100 |
Why?
|
| Muscle Proteins | 1 | 2016 | 551 | 0.100 |
Why?
|
| Compressive Strength | 1 | 2012 | 18 | 0.100 |
Why?
|
| Zebrafish Proteins | 1 | 2013 | 155 | 0.100 |
Why?
|
| Freeze Drying | 1 | 2012 | 31 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 2650 | 0.100 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2012 | 41 | 0.100 |
Why?
|
| Blood Vessels | 1 | 2013 | 232 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2013 | 266 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 16689 | 0.100 |
Why?
|
| Myristates | 1 | 2011 | 3 | 0.100 |
Why?
|
| Dansyl Compounds | 1 | 2011 | 6 | 0.100 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2012 | 243 | 0.100 |
Why?
|
| Survival Rate | 3 | 2020 | 12541 | 0.100 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 6177 | 0.100 |
Why?
|
| Hospitalization | 1 | 2020 | 2167 | 0.090 |
Why?
|
| Elongin | 1 | 2010 | 10 | 0.090 |
Why?
|
| Suppressor of Cytokine Signaling 1 Protein | 1 | 2010 | 20 | 0.090 |
Why?
|
| Flow Cytometry | 2 | 2015 | 3045 | 0.090 |
Why?
|
| Tissue Scaffolds | 1 | 2012 | 134 | 0.090 |
Why?
|
| Antioxidants | 1 | 2014 | 521 | 0.090 |
Why?
|
| Serum Albumin | 1 | 2011 | 246 | 0.090 |
Why?
|
| Salvage Therapy | 1 | 2019 | 2123 | 0.090 |
Why?
|
| Logistic Models | 1 | 2018 | 3444 | 0.090 |
Why?
|
| Cell Survival | 2 | 2018 | 3063 | 0.090 |
Why?
|
| Zebrafish | 1 | 2013 | 457 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2023 | 10400 | 0.090 |
Why?
|
| Aged | 11 | 2024 | 73333 | 0.090 |
Why?
|
| Thiones | 2 | 2008 | 19 | 0.090 |
Why?
|
| Ischemia | 1 | 2013 | 400 | 0.090 |
Why?
|
| Statistics as Topic | 1 | 2011 | 453 | 0.090 |
Why?
|
| Cadherins | 1 | 2013 | 657 | 0.090 |
Why?
|
| Iodipamide | 1 | 1990 | 3 | 0.090 |
Why?
|
| Inhibitor of Differentiation Protein 1 | 2 | 2007 | 16 | 0.090 |
Why?
|
| Diazepam | 1 | 1990 | 40 | 0.090 |
Why?
|
| Neoplasm Proteins | 2 | 2019 | 3345 | 0.090 |
Why?
|
| Statistical Distributions | 1 | 2009 | 7 | 0.090 |
Why?
|
| Rotarod Performance Test | 1 | 2009 | 24 | 0.090 |
Why?
|
| Adult | 12 | 2023 | 82040 | 0.090 |
Why?
|
| Thymus Gland | 2 | 2008 | 311 | 0.080 |
Why?
|
| Substrate Specificity | 1 | 2010 | 581 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 2 | 2018 | 2399 | 0.080 |
Why?
|
| Receptor, ErbB-2 | 1 | 2019 | 2651 | 0.080 |
Why?
|
| Kidney | 3 | 2024 | 2121 | 0.080 |
Why?
|
| Cell Adhesion | 1 | 2012 | 1028 | 0.080 |
Why?
|
| Fluorescent Dyes | 1 | 2011 | 467 | 0.080 |
Why?
|
| Soil | 2 | 2020 | 59 | 0.080 |
Why?
|
| Thiophenes | 2 | 2008 | 147 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2023 | 4961 | 0.080 |
Why?
|
| Bone Marrow | 2 | 2015 | 2441 | 0.080 |
Why?
|
| STAT5 Transcription Factor | 2 | 2008 | 226 | 0.080 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2009 | 154 | 0.080 |
Why?
|
| Histones | 1 | 2016 | 1513 | 0.080 |
Why?
|
| Carbon | 2 | 2020 | 165 | 0.080 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2009 | 69 | 0.080 |
Why?
|
| Models, Biological | 2 | 2010 | 3194 | 0.080 |
Why?
|
| Bone and Bones | 1 | 2012 | 605 | 0.080 |
Why?
|
| Muscle Strength | 1 | 2009 | 102 | 0.080 |
Why?
|
| Fatty Acids | 1 | 2011 | 440 | 0.080 |
Why?
|
| Disease Progression | 1 | 2020 | 6867 | 0.080 |
Why?
|
| Genes, Reporter | 2 | 2007 | 820 | 0.080 |
Why?
|
| Middle Aged | 10 | 2024 | 90352 | 0.080 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1335 | 0.080 |
Why?
|
| Radiation Chimera | 1 | 2008 | 33 | 0.080 |
Why?
|
| Beijing | 2 | 2018 | 13 | 0.080 |
Why?
|
| Rats, Wistar | 3 | 2019 | 598 | 0.080 |
Why?
|
| T-Cell Acute Lymphocytic Leukemia Protein 1 | 1 | 2007 | 10 | 0.080 |
Why?
|
| Mice, Knockout | 2 | 2016 | 5728 | 0.070 |
Why?
|
| Transcription Factor 7-Like 1 Protein | 2 | 2004 | 31 | 0.070 |
Why?
|
| 3T3 Cells | 1 | 2007 | 384 | 0.070 |
Why?
|
| TCF Transcription Factors | 2 | 2004 | 29 | 0.070 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2008 | 168 | 0.070 |
Why?
|
| HeLa Cells | 1 | 2010 | 1685 | 0.070 |
Why?
|
| Jurkat Cells | 1 | 2007 | 319 | 0.070 |
Why?
|
| Pyrazines | 2 | 2008 | 510 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2010 | 742 | 0.070 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2008 | 154 | 0.070 |
Why?
|
| Neural Stem Cells | 1 | 2008 | 182 | 0.070 |
Why?
|
| Janus Kinases | 1 | 2008 | 175 | 0.070 |
Why?
|
| Pyrazoles | 1 | 2015 | 1546 | 0.070 |
Why?
|
| DNA Methylation | 1 | 2016 | 2765 | 0.070 |
Why?
|
| United States | 6 | 2022 | 15861 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2015 | 6224 | 0.070 |
Why?
|
| Amino Acid Sequence | 3 | 2007 | 4567 | 0.070 |
Why?
|
| Janus Kinase 2 | 1 | 2010 | 754 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2007 | 1082 | 0.060 |
Why?
|
| Calcium-Binding Proteins | 1 | 2008 | 545 | 0.060 |
Why?
|
| Biomarkers, Tumor | 2 | 2024 | 10708 | 0.060 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 16215 | 0.060 |
Why?
|
| Porokeratosis | 1 | 2004 | 3 | 0.060 |
Why?
|
| Quality Control | 2 | 2018 | 461 | 0.060 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2008 | 593 | 0.060 |
Why?
|
| Phylogeny | 1 | 2007 | 867 | 0.060 |
Why?
|
| Mutation | 5 | 2024 | 15912 | 0.060 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 659 | 0.060 |
Why?
|
| Anticarcinogenic Agents | 1 | 2006 | 368 | 0.060 |
Why?
|
| Drug Liberation | 1 | 2024 | 19 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 2 | 2020 | 2454 | 0.060 |
Why?
|
| Biomarkers | 2 | 2022 | 5051 | 0.060 |
Why?
|
| Stromal Cells | 1 | 2008 | 825 | 0.060 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2004 | 162 | 0.060 |
Why?
|
| Administration, Cutaneous | 1 | 2024 | 141 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2020 | 2156 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2021 | 5759 | 0.060 |
Why?
|
| Risk Factors | 1 | 2020 | 17888 | 0.060 |
Why?
|
| Needles | 1 | 2024 | 108 | 0.060 |
Why?
|
| MAP Kinase Signaling System | 1 | 2008 | 885 | 0.050 |
Why?
|
| Povidone | 1 | 2023 | 13 | 0.050 |
Why?
|
| Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein | 1 | 2023 | 25 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2010 | 3145 | 0.050 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 4795 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2021 | 39890 | 0.050 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2004 | 223 | 0.050 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2003 | 51 | 0.050 |
Why?
|
| Aging | 1 | 2011 | 1534 | 0.050 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2023 | 202 | 0.050 |
Why?
|
| Clusterin | 1 | 2022 | 28 | 0.050 |
Why?
|
| Versicans | 1 | 2022 | 27 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2015 | 3669 | 0.050 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2015 | 2175 | 0.050 |
Why?
|
| Positive Transcriptional Elongation Factor B | 1 | 2022 | 37 | 0.050 |
Why?
|
| Glutaminase | 1 | 2023 | 70 | 0.050 |
Why?
|
| Calibration | 1 | 2023 | 346 | 0.050 |
Why?
|
| Molecular Sequence Data | 2 | 2007 | 6685 | 0.050 |
Why?
|
| Milk Proteins | 1 | 2003 | 127 | 0.050 |
Why?
|
| Transfection | 1 | 2007 | 3117 | 0.050 |
Why?
|
| Child | 2 | 2021 | 30559 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2023 | 210 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2021 | 3917 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-rel | 1 | 2002 | 26 | 0.050 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2023 | 288 | 0.050 |
Why?
|
| Time Factors | 5 | 2018 | 13006 | 0.050 |
Why?
|
| DNA, Complementary | 1 | 2003 | 938 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 1 | 2008 | 1757 | 0.050 |
Why?
|
| T-Lymphocytes | 3 | 2022 | 3949 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2015 | 4481 | 0.050 |
Why?
|
| Antigens, CD20 | 1 | 2022 | 207 | 0.050 |
Why?
|
| Polymers | 1 | 2023 | 222 | 0.050 |
Why?
|
| Cricetulus | 1 | 2021 | 214 | 0.050 |
Why?
|
| Glycosylation | 1 | 2021 | 230 | 0.050 |
Why?
|
| CHO Cells | 1 | 2021 | 320 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2008 | 1418 | 0.050 |
Why?
|
| Glutamine | 1 | 2023 | 324 | 0.050 |
Why?
|
| Tyrosine | 1 | 2022 | 508 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2022 | 322 | 0.050 |
Why?
|
| Soil Microbiology | 1 | 2020 | 18 | 0.050 |
Why?
|
| Nerve Tissue | 1 | 2020 | 11 | 0.050 |
Why?
|
| Receptors, Immunologic | 1 | 2022 | 313 | 0.050 |
Why?
|
| Histone Deacetylases | 1 | 2003 | 364 | 0.050 |
Why?
|
| Bias | 1 | 2021 | 216 | 0.050 |
Why?
|
| Insulin Resistance | 2 | 2016 | 732 | 0.050 |
Why?
|
| Sequence Deletion | 1 | 2003 | 909 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2002 | 249 | 0.040 |
Why?
|
| Base Sequence | 2 | 2004 | 5437 | 0.040 |
Why?
|
| Potentiometry | 2 | 1990 | 2 | 0.040 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2023 | 383 | 0.040 |
Why?
|
| Polyvinyl Chloride | 2 | 1990 | 9 | 0.040 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2021 | 350 | 0.040 |
Why?
|
| Membranes, Artificial | 2 | 1990 | 39 | 0.040 |
Why?
|
| Protein Domains | 1 | 2021 | 322 | 0.040 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2021 | 294 | 0.040 |
Why?
|
| Organelle Biogenesis | 1 | 2019 | 31 | 0.040 |
Why?
|
| Alkanes | 1 | 2019 | 4 | 0.040 |
Why?
|
| Information Dissemination | 1 | 2022 | 268 | 0.040 |
Why?
|
| Proteolysis | 1 | 2021 | 380 | 0.040 |
Why?
|
| Restaurants | 1 | 2019 | 23 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2022 | 878 | 0.040 |
Why?
|
| Ganglia, Spinal | 1 | 2020 | 251 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2023 | 1608 | 0.040 |
Why?
|
| Adsorption | 1 | 2018 | 50 | 0.040 |
Why?
|
| Necrosis | 1 | 2020 | 595 | 0.040 |
Why?
|
| Aerosols | 1 | 2019 | 150 | 0.040 |
Why?
|
| Inflammasomes | 1 | 2020 | 174 | 0.040 |
Why?
|
| Cell Movement | 2 | 2016 | 2472 | 0.040 |
Why?
|
| Biodegradation, Environmental | 1 | 2018 | 24 | 0.040 |
Why?
|
| Gases | 1 | 2018 | 39 | 0.040 |
Why?
|
| Skin | 1 | 2024 | 1271 | 0.040 |
Why?
|
| Hyperalgesia | 1 | 2020 | 244 | 0.040 |
Why?
|
| Haplotypes | 2 | 2015 | 910 | 0.040 |
Why?
|
| Polycyclic Aromatic Hydrocarbons | 1 | 2019 | 75 | 0.040 |
Why?
|
| Protein Stability | 1 | 2019 | 377 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2014 | 2311 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 4821 | 0.040 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 7265 | 0.040 |
Why?
|
| Ducks | 1 | 2017 | 9 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2024 | 1097 | 0.040 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2022 | 520 | 0.040 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2018 | 62 | 0.040 |
Why?
|
| Hypoxia | 1 | 2020 | 472 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2003 | 1424 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2023 | 1542 | 0.040 |
Why?
|
| Meat | 1 | 2017 | 94 | 0.040 |
Why?
|
| Behavior, Animal | 1 | 2020 | 747 | 0.040 |
Why?
|
| Polymerization | 1 | 2016 | 18 | 0.030 |
Why?
|
| Rituximab | 1 | 2022 | 1594 | 0.030 |
Why?
|
| Dipyridamole | 1 | 1996 | 41 | 0.030 |
Why?
|
| Orthopedic Procedures | 1 | 2018 | 145 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2003 | 1624 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2016 | 77 | 0.030 |
Why?
|
| Carotid Artery Injuries | 1 | 2016 | 50 | 0.030 |
Why?
|
| Proteasome Inhibitors | 1 | 2018 | 235 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2018 | 659 | 0.030 |
Why?
|
| GRB10 Adaptor Protein | 1 | 2016 | 19 | 0.030 |
Why?
|
| Catalysis | 1 | 2016 | 245 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2018 | 255 | 0.030 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2016 | 105 | 0.030 |
Why?
|
| Cytosol | 1 | 2016 | 267 | 0.030 |
Why?
|
| Hepatitis, Animal | 1 | 2015 | 5 | 0.030 |
Why?
|
| Diethylnitrosamine | 1 | 2015 | 38 | 0.030 |
Why?
|
| Carbon Tetrachloride | 1 | 2015 | 25 | 0.030 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2015 | 38 | 0.030 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2015 | 106 | 0.030 |
Why?
|
| Receptor, Insulin | 1 | 2016 | 110 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2023 | 1942 | 0.030 |
Why?
|
| Minority Groups | 1 | 2018 | 328 | 0.030 |
Why?
|
| Interferon-beta | 1 | 2015 | 109 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2022 | 13414 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2017 | 558 | 0.030 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2019 | 617 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2024 | 2359 | 0.030 |
Why?
|
| Biostatistics | 1 | 2014 | 20 | 0.030 |
Why?
|
| Transcription Factor RelA | 1 | 2015 | 184 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2003 | 1718 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 1996 | 230 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2002 | 1563 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2014 | 66 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2017 | 500 | 0.030 |
Why?
|
| Picrates | 1 | 2014 | 3 | 0.030 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2015 | 191 | 0.030 |
Why?
|
| Syndrome | 1 | 2018 | 1407 | 0.030 |
Why?
|
| Plants, Medicinal | 1 | 2014 | 49 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 30998 | 0.030 |
Why?
|
| Chlorambucil | 1 | 2014 | 26 | 0.030 |
Why?
|
| Phenotype | 3 | 2016 | 6509 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2018 | 379 | 0.030 |
Why?
|
| Immunologic Factors | 1 | 2018 | 672 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2014 | 224 | 0.030 |
Why?
|
| Actins | 1 | 2016 | 602 | 0.030 |
Why?
|
| Thalidomide | 1 | 2017 | 597 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 15218 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2018 | 1712 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2023 | 1840 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 497 | 0.030 |
Why?
|
| Oncogenes | 1 | 2016 | 699 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2014 | 590 | 0.030 |
Why?
|
| Escherichia coli Infections | 1 | 2015 | 272 | 0.030 |
Why?
|
| Aorta | 1 | 2016 | 670 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2016 | 1810 | 0.030 |
Why?
|
| Genomics | 1 | 2023 | 2835 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2015 | 1246 | 0.030 |
Why?
|
| Space Simulation | 1 | 2011 | 5 | 0.030 |
Why?
|
| Twin Studies as Topic | 1 | 2011 | 20 | 0.030 |
Why?
|
| Adenine | 1 | 2015 | 674 | 0.020 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2011 | 42 | 0.020 |
Why?
|
| Linear Models | 1 | 2014 | 1093 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2017 | 1516 | 0.020 |
Why?
|
| Aorta, Thoracic | 1 | 2016 | 534 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2015 | 1461 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2018 | 33737 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2015 | 699 | 0.020 |
Why?
|
| Nephrosis, Lipoid | 1 | 2010 | 12 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 1099 | 0.020 |
Why?
|
| Glucose | 1 | 2016 | 1218 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2014 | 2315 | 0.020 |
Why?
|
| Skin Neoplasms | 2 | 2019 | 4895 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 3035 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2018 | 2375 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2011 | 634 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 1990 | 87 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2015 | 5776 | 0.020 |
Why?
|
| Mathematics | 1 | 1990 | 141 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 1281 | 0.020 |
Why?
|
| Piperidines | 1 | 2015 | 1100 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2009 | 40 | 0.020 |
Why?
|
| Neurons | 1 | 2020 | 2439 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 1470 | 0.020 |
Why?
|
| Cell Separation | 1 | 2011 | 609 | 0.020 |
Why?
|
| Macrophages | 1 | 2015 | 1350 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2015 | 1136 | 0.020 |
Why?
|
| Aflatoxin M1 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Cellular Senescence | 1 | 2011 | 388 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2009 | 274 | 0.020 |
Why?
|
| DNA Mutational Analysis | 2 | 2004 | 2357 | 0.020 |
Why?
|
| Lateral Ventricles | 1 | 2008 | 25 | 0.020 |
Why?
|
| Ligands | 1 | 2011 | 1012 | 0.020 |
Why?
|
| Recurrence | 1 | 2017 | 4878 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 1571 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2009 | 295 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 5056 | 0.020 |
Why?
|
| Inhibitor of Differentiation Proteins | 1 | 2007 | 22 | 0.020 |
Why?
|
| Genotype | 1 | 2016 | 4252 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2011 | 1741 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2009 | 487 | 0.020 |
Why?
|
| Kinetics | 1 | 1990 | 2220 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 5162 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 3584 | 0.020 |
Why?
|
| HSC70 Heat-Shock Proteins | 1 | 2004 | 14 | 0.020 |
Why?
|
| Lod Score | 1 | 2004 | 173 | 0.020 |
Why?
|
| Models, Animal | 1 | 2007 | 657 | 0.010 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2004 | 175 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 5149 | 0.010 |
Why?
|
| Lung | 1 | 2015 | 3298 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2004 | 340 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2007 | 701 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2008 | 1368 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2004 | 198 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 4644 | 0.010 |
Why?
|
| Histone Deacetylase 1 | 1 | 2003 | 63 | 0.010 |
Why?
|
| Age of Onset | 1 | 2004 | 853 | 0.010 |
Why?
|
| Acetylation | 1 | 2003 | 515 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2018 | 17061 | 0.010 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2003 | 491 | 0.010 |
Why?
|
| Pedigree | 1 | 2004 | 2042 | 0.010 |
Why?
|
| Transgenes | 1 | 2002 | 576 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 22251 | 0.010 |
Why?
|
| Melanoma | 1 | 2014 | 5595 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 7381 | 0.010 |
Why?
|
| Adolescent | 1 | 2018 | 32767 | 0.010 |
Why?
|
| Chloroform | 1 | 1996 | 6 | 0.010 |
Why?
|
| Tablets | 1 | 1996 | 56 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 4130 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2011 | 3707 | 0.010 |
Why?
|
| Prognosis | 1 | 2014 | 22505 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2004 | 1696 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2004 | 2115 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 3339 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2007 | 7044 | 0.000 |
Why?
|